JP2010143932A5 - - Google Patents

Download PDF

Info

Publication number
JP2010143932A5
JP2010143932A5 JP2010002870A JP2010002870A JP2010143932A5 JP 2010143932 A5 JP2010143932 A5 JP 2010143932A5 JP 2010002870 A JP2010002870 A JP 2010002870A JP 2010002870 A JP2010002870 A JP 2010002870A JP 2010143932 A5 JP2010143932 A5 JP 2010143932A5
Authority
JP
Japan
Prior art keywords
antibody
srage
fragment
peptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010002870A
Other languages
English (en)
Other versions
JP2010143932A (ja
Filing date
Publication date
Priority claimed from US08/948,131 external-priority patent/US6555651B2/en
Application filed filed Critical
Publication of JP2010143932A publication Critical patent/JP2010143932A/ja
Publication of JP2010143932A5 publication Critical patent/JP2010143932A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 抗体または抗体の一部に結合されたペプチドであって、当該ペプチドは天然に存在するｓＲＡＧＥのＶドメインのアミノ酸１−３０またはアミノ酸２−３０を含むｓＲＡＧＥのフラグメントであり、当該ｓＲＡＧＥのフラグメントはアミノ酸２７０−２８１を含まない条件で当該抗体の一部分がＦｃフラグメントであるペプチド。
JP2010002870A 1997-10-09 2010-01-08 Ｒａｇｅのリガンド結合部位及びその使用 Pending JP2010143932A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/948,131 US6555651B2 (en) 1997-10-09 1997-10-09 Ligand binding site of rage and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000515619A Division JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用

Publications (2)

Publication Number Publication Date
JP2010143932A JP2010143932A (ja) 2010-07-01
JP2010143932A5 true JP2010143932A5 (ja) 2010-11-18

Family

ID=25487337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000515619A Withdrawn JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用
JP2010002870A Pending JP2010143932A (ja) 1997-10-09 2010-01-08 Ｒａｇｅのリガンド結合部位及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000515619A Withdrawn JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用

Country Status (12)

Country Link
US (1) US6555651B2 (ja)
EP (2) EP1023080B1 (ja)
JP (2) JP2001519401A (ja)
AT (1) ATE476192T1 (ja)
AU (1) AU9795898A (ja)
CY (1) CY1110884T1 (ja)
DE (1) DE69841806D1 (ja)
DK (1) DK1023080T3 (ja)
ES (1) ES2351876T3 (ja)
HK (1) HK1031100A1 (ja)
PT (1) PT1023080E (ja)
WO (1) WO1999018987A1 (ja)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
CA2346217A1 (en) * 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
AU6766800A (en) * 1999-08-13 2001-03-13 Trustees Of Columbia University In The City Of New York, The Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
US7423177B2 (en) 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
EP1724589A3 (en) * 2000-05-30 2007-04-25 TransTech Pharma Inc. Methods to identify compounds that modulate rage
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
AU2002245590B2 (en) 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
EP2324830A1 (en) 2002-03-05 2011-05-25 TransTech Pharma Inc. Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
CN1774445A (zh) * 2002-08-16 2006-05-17 惠氏公司 用于治疗rage相关病症的组合物和方法
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
NZ552128A (en) * 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
US20090060925A1 (en) * 2004-08-03 2009-03-05 The Trustees Of Columbia University In The City Of Rage Fusion Proteins and Methods of Use
WO2006034056A2 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
BRPI0517148A (pt) 2004-12-06 2008-09-30 Univ California método de aperfeiçoamento da estrutura e/ou função arterìola; agente ativo e kit para tratamento
EP1838339A2 (de) * 2005-01-18 2007-10-03 Abbott GmbH & Co. KG Ager-peptide und deren verwendung
US9291621B2 (en) * 2005-01-18 2016-03-22 AbbVie Deutschland GmbH & Co. KG AGER-peptides and use thereof
BRPI0608401A2 (pt) * 2005-03-17 2010-11-16 Columbia Univ New York polipeptìdeo, composição farmacêutica, ácido nucleico, vetor de expressão, célula, métodos para inibir a ligação entre diáfano e o domìnio citoplasmático de rage, para identificar um agente que inibe a ligação entre o diáfano e o domìnio citoplasmático de rage, e, uso de um agente que inibe a ligação entre diáfano e o domìnio citoplasmático de rage
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1890715A4 (en) * 2005-04-29 2009-10-28 Univ California PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
BRPI0620380B1 (pt) * 2005-12-23 2018-04-24 Gcoder Systems Ab Padrão de posicionamento
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
JP5558810B2 (ja) * 2006-05-05 2014-07-23 トランステック ファーマ，リミティド ライアビリティ カンパニー Ｒａｇｅ融合タンパク質、製剤及びその使用方法
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
ES2564634T3 (es) 2007-06-14 2016-03-28 Galactica Pharmaceuticals, Inc. Proteínas de fusión de RAGE
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
TWI517850B (zh) 2009-09-30 2016-01-21 Ｖｔｖ治療有限責任公司 經取代之咪唑衍生物及其使用方法
ES2550667T3 (es) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
JP5999542B2 (ja) * 2010-11-18 2016-09-28 国立研究開発法人農業・食品産業技術総合研究機構 リガンド様活性を有する分子の検出方法
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
KR101595630B1 (ko) * 2013-01-18 2016-02-18 성균관대학교산학협력단 Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
CA3110582A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
WO1995020979A1 (en) 1994-02-03 1995-08-10 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
EP0870040A2 (en) * 1995-12-29 1998-10-14 Chiron Corporation Gene delivery vehicle-targeting ligands
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
NZ331298A (en) * 1996-02-21 2000-03-27 Us Gov Health & Human Serv Recombinant (humanised) ribonuclease proteins derived from a native ribonuclease found in the oocytes of Rana pipiens and uses therefor
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof

Similar Documents

Publication Publication Date Title
JP2010143932A5 (ja)
JP2013523703A5 (ja)
ZA201802716B (en) Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
JP2014132019A5 (ja)
SMT201500125B (it) Anticorpi umani che legano il gene di attivazione dei linfociti-3 (lag-3) e loro usi
JP2012531046A5 (ja)
JP2014513951A5 (ja)
JP2013172734A5 (ja)
JP2015520667A5 (ja)
JP2012098988A5 (ja)
DK3029066T3 (da) Antistoffer med modificerede isoelektriske punkter
JP2011182796A5 (ja)
HK1215954A1 (zh) 蛋白、核酸、和抗體及其用途
JP2014518898A5 (ja)
JP2013538128A5 (ja)
JP2013540702A5 (ja)
WO2008094621A3 (en) Methods for allergen detection
WO2011056958A3 (en) Detection of traumatic brain injury
WO2012058292A3 (en) Parathyroid hormone variants and assays related to disease
JP2015516943A5 (ja)
JP2011236418A5 (ja)
CN301923368S (zh) 电动轿车车身（ej04 c）
CN301853019S (zh) 电动轿车车身（ej02 c）
CN301845331S (zh) 电动轿车车身（ej02 d）
CN301937700S (zh) 电动轿车车身（ej04 a）